(NASDAQ: CGC) Canopy Growth's forecast annual revenue growth rate of 8.88% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Canopy Growth's revenue in 2025 is $192,139,285.On average, 3 Wall Street analysts forecast CGC's revenue for 2026 to be $40,628,022,606, with the lowest CGC revenue forecast at $39,760,767,487, and the highest CGC revenue forecast at $42,309,012,297. On average, 3 Wall Street analysts forecast CGC's revenue for 2027 to be $43,467,019,186, with the lowest CGC revenue forecast at $41,188,599,426, and the highest CGC revenue forecast at $46,492,504,321.
In 2028, CGC is forecast to generate $45,707,289,350 in revenue, with the lowest revenue forecast at $45,707,289,350 and the highest revenue forecast at $45,707,289,350.